Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
- 1 January 1993
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 35 (1), 30-34
- https://doi.org/10.1111/j.1365-2125.1993.tb05666.x
Abstract
1. In microsomes prepared from three human livers, methadone competitively inhibited the O-demethylation of dextromethorphan, a marker substrate for CYP2D6. The apparent Ki value of methadone ranged from 2.5 to 5 microM. 2. Two hundred and fifty-two (252) white Caucasians, including 210 unrelated healthy volunteers and 42 opiate abusers undergoing treatment with methadone were phenotyped using dextromethorphan as the marker drug. Although the frequency of poor metabolizers was similar in both groups, the extensive metabolizers among the opiate abusers tended to have higher O-demethylation metabolic ratios and to excrete less of the dose as dextromethorphan metabolites than control extensive metabolizer subjects. These data suggest inhibition of CYP2D6 by methadone in vivo as well. 3. Because methadone is widely used in the treatment of opiate abuse, inhibition of CYP2D6 activity in these patients might contribute to exaggerated response or unexpected toxicity from drugs that are substrates of this enzyme.Keywords
This publication has 41 references indexed in Scilit:
- Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquineLife Sciences, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Serum levels of methadone in maintenance clients who persist in illicit drug useBritish Journal of Addiction, 1990
- Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)Biochemical and Biophysical Research Communications, 1988
- MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylationBiochemical and Biophysical Research Communications, 1987
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugsLife Sciences, 1983
- Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamineXenobiotica, 1979
- Synthesis and identification of metabolites resulting from the biotransformation of DL-methadone in man and in the ratJournal of Medicinal Chemistry, 1971
- The biotransformation of methadone in man: Synthesis and identification of a major metaboliteJournal of Pharmacy and Pharmacology, 1968